News Wire

At a White House briefing, Dr. Anne Schuchat, a deputy director of the Centers for Disease Control and Prevention, and Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, expressed concern about the threat the Zika virus poses to the United States. They said that…
The FDA has approved venetoclax (Venclexta, AbbVie/Genentech) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. Venetoclax is the first FDA-approved treatment that targets…
The U.S. Preventive Services Task Force (USPSTF) has released a final recommendation statement on the use of aspirin for the primary prevention of cardiovascular disease (CVD) and colorectal cancer. Evidence shows that low-dose aspirin use is most beneficial for adults 50 to 59 years of age, according…
The FDA has approved BioMonitor 2 (Biotronik), an insertable cardiac remote monitor designed to provide physicians with the ability to detect and diagnose atrial fibrillation, ventricular tachycardia and fibrillation, and syncope. The device can also be used to monitor atrial events in patients who…
A newly discovered antibiotic-resistant gene is threatening to open a new front in the war against “superbugs” by rendering a last-resort drug ineffective, experts warn. Dubbed mcr-1, the resistance-conferring gene easily transfers among bacteria found in humans, animals, or the environment. The…
The medical marketplace is about to get bigger. The FDA cleared a second biosimilar product—Inflectra (infliximab-dyyb, Janssen Biotech), a biosimilar to Remicade (infliximab, Janssen)—on April 5 and expects to approve other biosimilars in the future. The agency gave the nod to Zarxio (filgrastim-sndz,…
The Zika virus may be associated with an autoimmune disorder that attacks the brain’s myelin similar to multiple sclerosis, according to a new study presented at the American Academy of Neurology’s 68th annual meeting in Vancouver, Canada. “Though our study is small, it may provide evidence that…
A new plant-derived drug could be a step forward in preventing and treating multiple sclerosis (MS) and other autoimmune diseases, according to Dr. Christian Gruber, a researcher at the University of Queensland in Australia. “This is a really exciting discovery because it may offer a whole new quality…
The FDA has accepted a biologics license application (BLA) and granted a priority review designation for atezolizumab (Genentech) for the treatment of patients with locally advanced or metastatic non–small-cell lung cancer (NSCLC) whose disease expresses programmed death ligand-1 (PD-L1) proteins,…
Staff reviewers at the FDA have questioned whether the lung cancer treatment rociletinib (Clovis Oncology) is more effective than available treatments. The reviewers also recommended including a boxed warning in the drug’s label, if it is approved. The FDA’s Oncologic Drugs Advisory Committee (ODAC)…
An FDA safety review has found that type-2 diabetes medications containing saxagliptin or alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease. As a result, the agency has added new warnings and precautions to the labels of medications…
A new screening approach developed by Kaiser Permanente has been shown to close gaps in diagnosis and care for patients with hepatitis C virus (HCV) infection, according to new research published in Clinical Infectious Diseases. The screening protocol could improve disease detection for the more than…
A new data analysis has shown that levels of eosinophils can help identify patients with chronic obstructive pulmonary disease (COPD) who may or may not benefit from the addition of inhaled corticosteroid (ICS) treatment. The post hoc analysis was published online in Lancet Respiratory Medicine. The…
The FDA’s Gastrointestinal Drugs Advisory Committee has voted unanimously (17 to 0) to recommend accelerated approval of Ocaliva (obeticholic acid, Intercept Pharmaceuticals) for the treatment of patients with primary biliary cirrhosis, recently renamed primary biliary cholangitis (PBC). The target…
The Institute for Clinical and Economic Review (ICER), a nonprofit organization whose members include drug makers and insurers, has scheduled a meeting next month to review the value of multiple myeloma treatments and to determine a benchmark for payers. The meeting comes as concerns grow over the costs…

Pages

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA